Next, the analysis was restricted to patients with cytogenetically normal (CN) AML (n=183) because the influence of FLT3-ITD is most strong in CN-AML, which is re-classified as poor-risk category when ITD is accompanied. The gene discussed is FLT3; the disease is acute myeloid leukemia.